Results 141 to 150 of about 51,359 (249)

RAB4A acts as a negative feedback regulator of extracellular vesicle secretion during TGF‐β signaling

The FEBS Journal, EarlyView.
TGF‐β signaling regulates extracellular vesicle (EV) release in cancer cells by modulating the expression and activity of genes associated with EV biogenesis. The TGF‐β‐induced upregulation of RAB4A expression facilitates fast endosomal recycling, a process that limits the fusion of multivesicular bodies with the plasma membrane and EV secretion. Hence,
Dorival Mendes Rodrigues‐Junior, Maria Anastasia Doumani, Hao Fu, Jelle van den Bor, Olof Idevall‐Hagren, Aristidis Moustakas   +5 more
wiley   +1 more source

Dual IRE1 targets: Determinants of the cell fate?

The FEBS Journal, EarlyView.
IRE1 is an ER stress sensor that restores protein homeostasis through two signaling activities: XBP1s, which upregulates its target gene expression or RIDD which downregulates its target transcripts. We recently identified Dual IRE1 Targets (DIT) which are modulated by both XBP1s and RIDD activities.
Eva Billat, Léane Legrand, Tony Avril, Elodie Lafont   +3 more
wiley   +1 more source

Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. [PDF]

Oncoimmunology
Rosado-Sanz M, Martínez-Alarcón N, Meel MH, Rius-Perez S, Tolboom ZJ, Salvador-Coloma C, Burgos-Panadero R, Coronado E, Montoliu G, Casals E, Esteve-Codina A, Ripoll F, Santaballa A, Font de Mora J.   +13 more
europepmc   +1 more source

Setting dictates efficacy of pembrolizumab in TNBC [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

Physiological media and oxygen levels modulate cancer hallmarks in cultured breast cancer cells

The FEBS Journal, EarlyView.
MCF7 breast cancer cells were cultured in standard conditions (18% O2 and DMEM) and physiological conditions (5% O2 and Plasmax, a medium modeled after the human plasma metabolome). A combined transcriptomic and proteomic approach was used to identify gene expression signatures at the mRNA and protein levels upstream of functional enrichment analyses ...
Jacob E. Wiebe, Ricardo Alva, Fereshteh Moradi, Sarah Alderman, Ping Liang, Jeffrey A. Stuart   +5 more
wiley   +1 more source

TNBC

KILIÇ ERCİYAS, Seda, TUNCER, SEREF BUGRA   +1 more
openaire   +2 more sources

UK recommendations for Ki‐67 immunohistochemical staining and interpretation in breast cancer

Histopathology, EarlyView.
Where possible, a validated digital imaging system should be utilized. If this is not available, then intermediate scores (5%–30%) should be thoroughly assessed using the Ki‐67 International Working Group guidance. Difficult cases should be double scored.
Abeer M Shaaban, Andrew Dodson, Emad Rakha, Ian Ellis, Daniel Rea, Cecily Quinn, Elena Provenzano, Sarah Pinder, on behalf of the UK National Coordinating Committee for Breast Pathology (NCCBP), Association of Breast Pathology (ABP) and the UK National External Quality Assessment Scheme for Immunohistochemistry and In Situ Hybridisation (UK NEQAS ICC & ISH)   +9 more
wiley   +1 more source

The YAP-TEAD4 inhibitor M511-0965 suppresses triple-negative breast cancer progression by downregulating TGFB2. [PDF]

Transl Oncol
Cheng M, Li X, Song N, Yang X, Ma X, Zhang H, Lei Y, Jia Y, Ba L, Zhang R, Bai L, Xu W, Qiao G.   +12 more
europepmc   +1 more source

The Emerging Role of UCHL1 in Neurological and Musculoskeletal Diseases

Immunology &Cell Biology, EarlyView.
UCHL1‐associated pathology. The pathological role of UCHL1 in multisystem diseases, including cancer, neurological, musculoskeletal and cardiovascular disorders. ABSTRACT Ubiquitin C‐terminal hydrolase L1 (UCHL1) is a highly conserved deubiquitinating enzyme that has transitioned from being viewed as a “brain‐specific” protein to a global regulator of ...
Ru Feng, Xiu Zhong, Jianjun Li, Adrian A. Achuthan   +3 more
wiley   +1 more source

Development and internal validation of a nomogram based on HER2 status for predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. [PDF]

Transl Cancer Res
Chai X, Wei C, Yang T, Zhou H, Du X, Wang Q, Zhang T, Long J.   +7 more
europepmc   +1 more source